Kim Min-Ju, Chu Ki-Back, Lee Su-Hwa, Kang Hae-Ji, Yoon Keon-Woong, Ahmed Md Atique, Quan Fu-Shi
Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul 02447, Korea.
Medical Research Center for Bioreaction to Reactive Oxygen Species and Biomedical Science Institute, School of Medicine, Graduate School, Kyung Hee University, Seoul 02447, Korea.
Trop Med Infect Dis. 2022 Nov 4;7(11):350. doi: 10.3390/tropicalmed7110350.
Recombinant vaccinia viruses (rVV) are effective antigen delivery vectors and are researched widely as vaccine platforms against numerous diseases. Apical membrane antigen 1 (AMA1) is one of the candidate antigens for malaria vaccines but rising concerns regarding its genetic diversity and polymorphism have necessitated the need to search for an alternative antigen. Here, we compare the efficacies of the rVV vaccines expressing either AMA1 or microneme protein (MIC) of in mice. Mice (BALB/c) were immunized with either rVV-AMA1 or rVV-MIC and subsequently challenge-infected with Compared to the control group, both antigens elicited elevated levels of parasite-specific antibody responses. Immunization with either one of the two vaccines induced high levels of T cells and germinal center B cell responses. Interestingly, rVV-MIC immunization elicited higher levels of cellular immune response compared to rVV-AMA1 immunization, and significantly reduced pro-inflammatory cytokine productions were observed from the former vaccine. While differences in parasitemia and bodyweight changes were negligible between rVV-AMA1 and rVV-MIC immunization groups, prolonged survival was observed for the latter of the two. Based on these results, our findings suggest that the rVV expressing the MIC could be a vaccine-candidate antigen.
重组痘苗病毒（rVV）是有效的抗原递送载体，作为针对多种疾病的疫苗平台被广泛研究。顶膜抗原1（AMA1）是疟疾疫苗的候选抗原之一，但对其遗传多样性和多态性的日益关注使得有必要寻找替代抗原。在此，我们比较了在小鼠中表达AMA1或微小膜泡蛋白（MIC）的rVV疫苗的效力。用rVV-AMA1或rVV-MIC免疫小鼠（BALB/c），随后用[具体疟原虫名称缺失]进行攻击感染。与对照组相比，两种抗原均引发了寄生虫特异性抗体反应水平的升高。用两种疫苗中的任何一种进行免疫均诱导了高水平的T细胞和生发中心B细胞反应。有趣的是，与rVV-AMA1免疫相比，rVV-MIC免疫引发了更高水平的细胞免疫反应，并且观察到前一种疫苗的促炎细胞因子产生显著减少。虽然rVV-AMA1和rVV-MIC免疫组之间的寄生虫血症和体重变化差异可忽略不计，但观察到后者的存活时间延长。基于这些结果，我们的研究结果表明，表达[具体疟原虫名称缺失] MIC的rVV可能是一种候选疫苗抗原。
